Australasian COVID-19 Trial ASCOT is a clinical trial that will generate clinical evidence about treatment for COVID-19 that can be applied during the pandemic to reduce mortality or the need for mechanical ventilation in hospitalised but not yet critically ill patients with COVID-19.
Trial Overview
1602 patients enrolled in trial
1602 patients randomised
43 sites activated
ASCOT closes the Anticoagulation Treatment Domain
April 14, 2022
On Thursday, 7 April 2022, the ASCOT Trial Steering Committee (TSC), with support from the Anticoagulation Domain-Specific Working Group (DSWG), ma...
COVID-19 clinical trials disproportionately run out of high-income countries research shows
February 26, 2022
ASCOT randomises 1,000th patient
October 12, 2021
Australasian COVID-19 Trial (ASCOT) reached an important milestone on Tuesday, 21 September 2021, randomising the 1,000th patient into the study. T...
The ASCOT Process
01. Identify potential treatment options
02. Evaluate candidate treatments
03. Identify effective treatments & disregard ineffective treatments
04. Generate clinical evidence that can be applied during the pandemic and within the trial itself
Use left/right arrows to navigate the slideshow or swipe left/right if using a mobile device
